Amrutanjan Health Care Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹135 Cr +14.4% YoYSee revenue, profit and what management said. You are viewing Q3 FY25.
AH

Amrutanjan Health Care Ltd

Q3 FY25Pharmaceuticals & Biotechnology

Amrutanjan Health Care Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹123Cr
+5.1% YoY
+11.8% QoQ
Net profit
₹19Cr
+11.8% YoY
+58.3% QoQ
Margin
19%
+1 pp YoY
+7 pp QoQ

Based on Amrutanjan Health Care Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹510
Market cap₹1.4K Cr
P/E23.0

The short version

Q3 FY25 Net Sales: Rs. 122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. 116.99 Cr). Quarterly EBITDA/Operating Margin:.

From Amrutanjan Health Care Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3 FY25 Net Sales: Rs. 122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. 116.99 Cr)
  • Q3 FY25 Net Sales - OTC: Rs. 117.86 Cr, up 5.43% YoY (Q3 FY24: Rs. 111.79 Cr)
  • Q3 FY25 Net Sales - Comfy: Rs. 29.93 Cr, up slightly from Rs. 29.36 Cr YoY
  • Q3 FY25 Net Sales - Beverages: Rs. 4.42 Cr, down from Rs. 5.18 Cr YoY
  • Q3 FY25 Net Sales - Electro Plus: Rs. 4.31 Cr, down from Rs. 4.62 Cr YoY
  • YTD Dec’24 Net Sales: Rs. 316.40 Cr, up 7.56% YoY (YTD Dec’23: Rs. 294.17 Cr)
  • YTD Dec’24 OTC Division Sales: Rs. 296.75 Cr, up 9.09% YoY (YTD Dec’23: Rs. 272.02 Cr)
  • Pain balm consumption volume growth in Dec quarter: 9.1% (IQVIA), highest in 20 quarters (excluding COVID)

2 more points from Amrutanjan Health Care Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.

Amrutanjan Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Amrutanjan Health Care Ltd Q3 FY25 results — key figures

Amrutanjan Health Care Ltd Q3 FY25 reported results vs Q3 FY24, ₹ crore
₹ CrQ3 FY25Q3 FY24YoYQ2 FY25QoQ
Revenue123117+5.1%110+11.8%
Operating profit (EBITDA)2322+4.5%14+64.3%
Operating margin19%18%+1 pp12%+7 pp
Profit before tax2624+8.3%16+62.5%
Net profit (PAT)1917+11.8%12+58.3%
EPS (₹)6.666.04+10.3%4.08+63.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • SMS Pharmaceuticals (Q3 FY25)

    Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Wockhardt (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…

  • NGL Fine Chem (Q3 FY25)

    Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…

  • Shree Ganesh Rem (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Amrutanjan Health Care Ltd Q3 FY25 results?

Q3 FY25 Net Sales: Rs. 122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. 116.99 Cr). Quarterly EBITDA/Operating Margin:.

What is Amrutanjan Health Care Ltd share price analysis?

Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.